Europe Grants Limited Approval to Eli Lilly's (LLY) Alzheimer's Drug
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The treatment for early-onset Alzheimer's, which is administered via a monthly infusion, has already been approved in the U.S., United Kingdom (U.K.), Japan and China. In March, the European Medicines Agency human medicines committee rejected the drug, saying there was a risk of 'potentially fatal events' due to brain injuries and bleeding.
But now, after re-examining the drug at the request of Eli Lilly, the medicines committee has recommended granting Kisunla marketing authorization for a limited number of patients who do not have a copy, or only have one copy, of the ApoE4 gene that puts them at a greater risk of Alzheimer's disease.
Controlled Access
The EMA said the treatment should be administered as part of a controlled access program and under the supervision of physicians trained in managing potentially dangerous symptoms. It also mandated measures aimed at mitigating risks, including more stringent rules for stopping treatment, and said that patients administered Kisunla must start with a low dose.
'This positive opinion marks a significant milestone in our efforts to bring (Kisunla) to eligible patients across Europe,' said Patrik Jonsson, President of Eli Lilly International, in a written statement. '(Kisunla) has the potential to make a meaningful difference for people living with early symptomatic Alzheimer's disease.'
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,006.80 implies 26.02% upside from current levels.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
11 hours ago
- CNBC
Cramer's week ahead: Earnings from Palantir, Berkshire Hathaway, Disney and McDonald's
CNBC's Jim Cramer walked investors through another week of earnings season, honing in on reports from Palantir, Berkshire Hathaway, Disney and Eli Lilly. "We're still in earnings Hades, but at least it's getting a little cooler out there," he said. "That's right, we've now gotten over the hump of the big-time growth stocks, the hyperscalers, but there's plenty left." On Saturday, Cramer will be paying attention to earnings from Berkshire Hathaway, and he suggested things might be a little different with Greg Abel at the helm. If the report is good, Cramer said he bets the stock goes higher. Monday, Cramer is watching Palantir's report. He has called the company, which just landed a $10 billion Army contract, "the most controversial stock in the entire market." He said the data outfit has excited many on Wall Street. And he predicted the quarter will be "a total blowout," as it seems business is strong. Tuesday brings quarterly results from DuPont De Nemours, Caterpillar, Pfizer and Marriott. Cramer said it's important to see that DuPont's breakup is on track, because the parts are worth more than the whole for the chemical company. He suggested Caterpillar will post strong results as the equipment manufacturer rides the tailwinds of domestic infrastructure and reshoring. To Cramer, it's necessary that Pfizer sees some "really dramatic" results from clinical trials because the pharmaceutical giant's shareholder base is "getting very restive." Marriott is usually reliable, he continued, but said the hotel chain's stock tends to come down after earnings even if the results are good. Disney and McDonald's are set to report on Wednesday. Shares of the media titan have been climbing nicely, Cramer said, and he praised the streaming, theme park and cruise line business segments. He also said McDonald's is a buy at current levels, suggesting the company has improved as of late with new offerings for customers. Dutch Bros and E.l.f Beauty, two young "renegade" companies that have shaken up business in their respective sectors, will also report Wednesday, Cramer said. He added that he thinks they both have room to grow and take share. Thursday brings earnings from Eli Lilly. Cramer pointed out that its main competitor in the GLP-1 drug arena, Novo Nordisk, just posted a disappointing quarter. He wondered whether Novo Nordisk's results indicate that Eli Lilly has been taking share or if both companies are seeing a peak in their popular weight loss medication. He said both dynamics could be true. Warner Bros Discovery, MP Materials, Wynn Resorts and Pinterest are also set to report on Thursday. Cramer said he's waiting to hear how Warner Bros is reorganizing the company and paying down debt. He said he wants to learn about rare earth mineral miner MP Materials' deal with the U.S. government. He also said he's feeling positive about Wynn Resorts. Pinterest is likely to post a solid report, he continued, and said it's the most family-friendly advertising platform compared to its peers. Wendy's will post earnings on Friday, and Cramer said the previous quarter was weak. He suggested the sector is so competitive that there are no guarantees the burger chain will share good results. Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest The CNBC Investing Club Charitable Trust owns share of DuPont de Nemours, Disney and Eli Lilly.
Politico
16 hours ago
- Politico
Senate appropriators defend the NIH
WASHINGTON WATCH Senate appropriators came out hard in support of the National Institutes of Health on Thursday, giving the agency a $400 million funding boost for the 2026 fiscal year. How so: The Senate Appropriations Committee upped the agency's budget to $48.7 billion in the 2026 funding bill that cleared the panel with a 26-3 vote Thursday. If the bill becomes law, it would increase cancer research by $150 million; Alzheimer's research by $100 million and amyotrophic lateral sclerosis, or ALS, research by $25 million. The NIH's National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health would each get a $30 million boost. Research on maternal mortality, diabetes and rare diseases would also see an increase, among others. Why it matters: The funding boost is a rebuke from both Republicans and Democrats to the Trump administration's demand to decrease the NIH funding in the next fiscal year by as much as 40 percent, or $18 billion. Senate Appropriations Chair Susan Collins (R-Maine) said the legislation 'prioritizes funding to help make Americans healthier and supports life-saving medical research.' Sen. Patty Murray (D-Wash.), the top Democrat on the panel, said the budget increase was a message to 'the scientists wondering if there will even be an NIH by the end of this administration. This committee's resounding message is: 'Yes, Congress has your back.'' Murray urged scientists to continue their research in the U.S. despite the efforts of other countries to lure them away. The appropriators also adopted an amendment Thursday that would limit the Trump administration's control over NIH research funding. An amendment in the bill's manager's package limits the administration's plan to shift funding for most NIH grants from a multiyear schedule to an upfront single-year payment. The amendment states that no funds appropriated in the fiscal 2026 spending bill can be used to increase the proportion of grants fully funded in the first year of the award, compared with fiscal 2024. The NIH can only increase that proportion of forward-funded grants if the agency ensures it isn't cutting grants to do so. What's next: The bill is cleared for floor action. But congressional leaders haven't started bipartisan negotiations toward overall government funding totals, increasing the odds that lawmakers will again resort to a stopgap funding patch before the next fiscal year starts on Oct. 1. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Peacock feathers have reflective structures that can amplify light into a laser beam, Science reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs, or court rulings could ripple through the economy? Start here. WORLD VIEW A draft United Nations plan to make the world healthier no longer includes several targets cracking down on sugary drinks, trans fats and tobacco to prevent and control noncommunicable diseases globally. Struck down: A target of 80 percent of countries taxing sugary drinks at levels recommended by the World Health Organization by 2030, POLITICO's Rory O'Neill reports. That goal was a pillar of the initial draft, which will take the form of a nonbinding political declaration world leaders are expected to endorse at a Sept. 25 meeting in New York, on the margins of the U.N. General Assembly. The latest version has also dropped commitments to eliminate trans fats and aims instead to reduce them to the 'lowest level possible.' It also requires front-of-pack labels with nutritional information. A requirement for health warnings on tobacco packaging to be graphic and accompanied by elements that make it unattractive to consumers is also gone. The new draft has softer language on tobacco advertising, requiring countries to restrict it instead of eliminate it. 'Make no mistake, the Declaration in its current form is a backslide,' said Alison Cox, director of policy and advocacy at the NCD Alliance, in a statement. The alliance is a Switzerland-based civil society group working to promote chronic disease prevention. Why it matters: World leaders aim to reduce premature mortality from noncommunicable diseases such as heart disease, cancer and diabetes by 2030 through prevention and treatment and to improve mental health and well-being globally. Noncommunicable diseases killed 18 million people under age 70 in 2021, according to the WHO. Most deaths were in low- and middle-income countries. The aims align with the U.S. Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda, but it's unclear how much the U.S. is involved in drafting the final text. HHS did not respond to a request for comment. What's next: Negotiators are meeting this week in New York to discuss the text.
Yahoo
20 hours ago
- Yahoo
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
Key Points Eli Lilly is leading the way in the GLP-1 weight-loss revolution. AbbVie is finding new avenues of growth after its Humira patent loss. Pfizer has some short-term challenges, but the business is still in great shape. 10 stocks we like better than Eli Lilly › Great businesses have a habit of remaining so even when market volatility arises. The stock market is cyclical, and ups as well as downs are inevitable. When you only buy stocks that you have strong convictions about as long-term investments (based on sound research, your financial goals, and proper risk tolerance), you can hold onto those companies through the downturns and benefit during the bull periods. While the stock market has been on a strong winning streak recently, you should only be putting cash into stocks that you want to hold for at least three to five years. Dividend stocks can be a great way to boost your returns through time, both with share-price appreciation and with consistent payouts that you can save or reinvest as you like. If you have cash to invest right now that you don't need for bills or other financial obligations, here are three dividend healthcare stocks to consider for your next round of investments. 1. Eli Lilly Eli Lilly (NYSE: LLY) has been paying a dividend in some form since 1885. And while the yield is below 1% right now, that's partly a function of the stock's incredible total return of more than 400% over the last five years. The company has garnered plenty of interest from investors during that period thanks to its GLP-1 franchise. The success of Mounjaro and Zepbound has certainly ushered Lilly into a new era of growth, and shareholders have benefited in the process. Although shares dipped after the company's first-quarter earnings release -- partly due to lowered profit expectations because Novo Nordisk secured a preferred listing deal with CVS Health for its rival GLP-1 weight loss drug -- this is still a rock-solid company with a robust growth runway ahead. Eli Lilly was one of the oldest and leading drugmakers in the world before Mounjaro and Zepbound, and it already had an established presence in the diabetes-care space. In fact, Lilly was a pioneer in insulin production, becoming the first company to mass-produce and commercially sell insulin in the U.S. with its product called Iletin in 1923. It later developed Humulin, the first biosynthetic human insulin, which was approved in 1982 and further solidified Lilly's position in diabetes care. Aside from its current blockbuster GLP-1 portfolio, which helped deliver revenue just shy of $13 billion (up 45% year over year) in Q1 alone, Eli Lilly boasts more top-selling portfolio makers. Other notable drugs include Trulicity (for diabetes), Verzenio (a breast cancer drug), and Taltz (for psoriasis and related conditions). Newer additions to the company's portfolio include Omvoh, for inflammatory bowel disease, and Kisunla for Alzheimer's disease. Watch for updates on Lilly's next-gen GLP-1 drug, orforglipron, an oral, small-molecule medication that's being studied for both weight loss and diabetes treatment. The drug is now in seven separate late-stage trials for diabetes and obesity. The company plans to submit it for approval to the Food and Drug Administration (FDA) as a weight loss medication later this year, and for diabetes treatment in 2026. And with Eli Lilly commanding a 53% share of the GLP-1 market, the long-term potential of this storied business may still be in its early stages. 2. AbbVie AbbVie (NYSE: ABBV) boasts Dividend King status at this point, having raised its payout every single year for more than five decades and counting. The stock currently yields about 3.4% based on current share prices. AbbVie has delivered robust financial performance of late, with notable revenue growth from its immunology portfolio. That growth has been driven by longtime blockbusters like Skyrizi and Rinvoq. Profitable drugs like these have been instrumental in the transitional period of the last few years following AbbVie's loss of patent exclusivity for Humira, which at one point was the world's top-selling drug. The company's oncology portfolio is currently bolstered by lucrative drugs like Imbruvica and Venclexta. Its neuroscience portfolio, including drugs like Vraylar and Botox Therapeutic, is also providing a lift. In Q1 2025, AbbVie reported an 8.4% year-over-year increase in net revenue to $13.3 billion. Its adjusted diluted earnings per share increased 6.5% to $2.46. The company also raised its full-year 2025 guidance for both revenue and adjusted diluted earnings per share. AbbVie garnered its eighth approved indication for its blockbuster Rinvoq in the EU in the quarter (for the treatment of giant cell arteritis in adult patients), and this is a drug that brought in nearly $2 billion in Q1 alone. The company is in the process of seeking approval for trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines ("frown lines"). This candidate is intended to offer a faster-acting, shorter-duration alternative to existing neurotoxins for patients seeking treatment, and if approved would be the first commercialized neurotoxin of its kind. AbbVie has announced a collaboration with Xilio Therapeutics to develop novel immunotherapies for various cancers. It also marked its first foray into the obesity field, announcing a licensing agreement with Danish biotech Gubra to develop a long-acting amylin analog. There's a lot to like about this healthcare stock besides its dividend, as the company's profitable business has driven shares upward by about 100% in the trailing five-year period alone. If you're a long-term buy-and-hold investor, this could be a dividend stock worth considering for your basket of buys. 3. Pfizer Pfizer (NYSE: PFE) hasn't gotten a lot of love from investors since its peak in 2021-2022. While shares are now trading much lower, near levels not seen in close to a decade, that has pushed the company's yield up to a mouthwatering 7%. It's worth noting that Pfizer has a long history of paying dividends, going back to 1974; it has consistently paid quarterly since then. It has also increased its dividend every year since 2010. So why has the market been so tough on Pfizer? For starters, the demand for its COVID-19 vaccine Comirnaty and treatment Paxlovid has decreased significantly as the pandemic has fallen further in the rearview mirror. This decline in sales was anticipated, but has still impacted overall revenue. Moreover, several of Pfizer's blockbuster drugs are facing patent expirations in the next few years, which means generic versions will become available, eroding their market share and revenue. Patent losses are a normal and expected part of the business life cycle of every drug, and a reality that pharmaceutical giants plan for years in advance. Pfizer used the billions of dollars in cash and profits it derived from its COVID-19 products to implement a series of strategic acquisitions, including the $43 billion purchase of Seagen. This alone roughly doubled Pfizer's oncology drug pipeline to 60 programs, added four FDA-approved cancer drugs (Adcetris, Padcev, Tivdak, and Tukysa), and is likely to help achieve the company's goal of having eight or more blockbuster oncology drugs by 2030. Management said a few years ago that its combination of deals along with internal development would add $20 billion or more in annual revenue by the beginning of the next decade, which should amply offset the roughly $17 billion to $18 billion that's estimated will be lost to patent expirations. Meanwhile, in Q1, Pfizer brought in total profits of about $3 billion on revenue of $13.7 billion. Those figures were driven by numerous key drugs including the Vyndaqel family of medicines (for cardiomyopathy caused by transthyretin-mediated amyloidosis), Padcev (for advanced urothelial cancer), Nurtec (for migraine treatment and prevention), and Lorbrena (for non-small cell lung cancer). Those four products alone clocked year-over-year sales increases of 33%, 25%, 40% and 39%, respectively. Pfizer also returned $2.4 billion to shareholders through dividends. This hardly looks like the tale of a business with its best days behind it. If you're patient and willing to ride out near-term volatility, you can enjoy some healthy dividend income while you wait. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool recommends CVS Health and Novo Nordisk. The Motley Fool has a disclosure policy. 3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
